Eli Lilly’s oral obesity drug Foundayo cleared a key cardiovascular safety hurdle in people with type 2 diabetes, meeting a primary non-inferiority objective in a heart outcomes study versus insulin glargine. Lilly said there was no greater risk of major adverse cardiovascular events and no added signal for liver injury, while also reporting improvements in glycemic and weight outcomes for patients who remained on treatment. Separately, reporting on Lilly’s Phase 3 Achieve-4 readout indicated Foundayo also demonstrated favorable efficacy trends on cardiovascular endpoints, setting up an incremental step-change for an already crowded obesity market. The company plans to seek FDA approval in diabetes and use a national priority review voucher, positioning the pill to expand beyond obesity into a larger diabetes-and-obesity segment.